As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
|Videos|August 14, 2020
How Pharmacists Can Find Their Niche on Social Media
Stephanie Moss, PharmD, MS, is going live each Wednesday evening on the Pharmacy Times Instagram and Facebook pages. Tune in each week to learn more about establishing a presence on social media and join the discussion.
Advertisement
On Wednesday, Stephanie Young Moss, PharmD, MS, continued discussing how pharmacists can find their niche on social media. Finding a niche can be challenging, Moss said, especially in the broad field of pharmacy.
For example, Moss said that starting a Facebook page to discuss drugs is too broad and would be too confusing for patients trying to find specific information. A better niche would be prenatal drugs or drugs for type 2 diabetes.
“Those are all things that you can niche down to,” Moss said. “Instead of just talking about every single drug, make sure that you narrow it down and talk about only certain drugs. That will really help.”
When considering your niche, Moss encouraged pharmacists to consider what she calls the “N.I.C.E. Niche” framework. A niche should have a need from the public, should be innovative and competitive, and people should have an expertise in that area, according to Moss.
“This should help you find your niche that’s right for you,” Moss said.
Advertisement
Related to this article
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
4
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
5